Gastrointestinal Neuroendocrine Tumors of the Esophagus/Stomach

Gastrointestinal Neuroendocrine Tumors of the Esophagus/Stomach — Trials · CancerIndex

Clinical trials

Registered studies

3 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1
Recruiting: 0
Ph III recruiting: 0
Growth YoY: —
Industry share: 0%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (0)

clinicaltrialsPublishedShowing 1–3 of 3 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00569127	Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor	active not recruiting	Phase 3	427	National Cancer Institute (NCI)NIH	1	Aug 28, 2026	clinicaltrials
NCT02420691	Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin	completed	Phase 2	21	M.D. Anderson Cancer CenterOTHER	1	Oct 30, 2020	clinicaltrials